The clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in newly diagnosed and recurrent IDH-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.

被引：0
|
作者：
Lombardi, Giuseppe
Giunco, Silvia
Cavallin, Francesco
Angelini, Chiara
Caccese, Mario
Cerretti, Giulia
De Bonis, Pasquale
De Rossi, Anita
Zagonel, Vittorina
机构：
[1] IRCCS, Veneto Inst Oncol, Oncol 1, Dept Oncol, Padua, Italy
[2] IRCCS, Veneto Inst Oncol IOV, Immunol & Mol Oncol Unit, Padua, Italy
[3] Univ Ferrara, Ferrara, Italy
[4] Dept Translat Med, Neurosurg, Ferrara, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2053
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2053
引用
收藏
页数：2
相关论文
共 10 条
  • [1] THE CLINICAL SIGNIFICANCE OF TELOMERASE REVERSE TRANSCRIPTASE (TERT) PROMOTER MUTATIONS, TELOMERE LENGTH AND O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS IN NEWLY DIAGNOSED AND RECURRENT IDHWILDTYPE GLIOBLASTOMA (GBM) PATIENTS (PTS): A LARGE MONO-INSTITUTIONAL STUDY.
    Lombardi, G.
    Giunco, S.
    Cavallin, F.
    Angelini, C.
    Caccese, M.
    Cerretti, G.
    De Bonis, P.
    De Rossi, A.
    Zagonel, V.
    NEURO-ONCOLOGY, 2021, 23 : 1 - 2
  • [2] THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY
    Lombardi, Giuseppe
    Giunco, Silvia
    Cavallin, Francesco
    Angelini, Chiara
    Caccese, Mario
    Cerretti, Giulia
    De Bonis, Pasquale
    De Rossi, Anita
    Zagonel, Vittorina
    NEURO-ONCOLOGY, 2021, 23 : 15 - 15
  • [3] Clinical significance of telomerase reverse transcriptase (TERT) promoter mutations, telomere length and MGMT promoter methylation status in newly diagnosed and recurrent IDHwildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study
    Lombardi, G.
    Giunco, S.
    Cavallin, F.
    Angelini, C.
    Caccese, M.
    Cerretti, G.
    De Bonis, P.
    De Rossi, A.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S523 - S523
  • [4] Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
    Weller, M.
    Gramatzki, D.
    Felsberg, J.
    Hentschel, B.
    Wolter, M.
    Schackert, G.
    Westphal, M.
    Regli, L.
    Thon, N.
    Tatagiba, M.
    Wick, W.
    Schlegel, U.
    Krex, D.
    Roth, P.
    Rushing, E.
    Pietsch, T.
    von Deimling, A.
    Sabel, M.
    Loeffler, M.
    Reifenberger, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S396 - S396
  • [5] TREATMENT OUTCOMES OF NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTER (MGMT) STATUS: A MULTI-COUNTRY STUDY
    Fu, A. Z.
    Hall, J. P.
    Bailey, A.
    Kemp, J.
    Thompson, G. J.
    Lee, C.
    NEURO-ONCOLOGY, 2019, 21 : 73 - 73
  • [6] TREATMENT PATTERNS BY O6-METHYLGUANINE DNA METHYLTRANSFERASE PROMOTER (MGMT) STATUS IN NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A MULTI-COUNTRY CHART REVIEW STUDY
    Fu, A. Z.
    Thompson, G. J.
    Hall, J. P.
    Bailey, A.
    Kemp, J.
    Lee, C.
    NEURO-ONCOLOGY, 2019, 21 : 75 - 75
  • [7] Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
    Stupp, Roger
    Hegi, Monika E.
    Goriia, Thierry
    Erridge, Sara
    Grujicic, Danica
    Steinbach, Joachim Peter
    Wick, Wolfgang
    Tarnawski, Rafal
    Nam, Do-Hyun
    Weyerbrock, Astrid
    Hau, Peter
    Taphoorn, Martin J. B.
    Nabors, Louis B.
    Reardon, David A.
    Van den Bent, Martin J.
    Perry, James R.
    Hong, Yong Kil
    Hicking, Christine
    Picard, Martin
    Weller, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM) - CheckMate-548
    Weller, M.
    Vlahovic, G.
    Khasraw, M.
    Brandes, A. A.
    Zwirtes, R.
    Tatsuoka, K.
    Carpentier, A. F.
    Reardon, D. A.
    van den Bent, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study.
    Stupp, Roger
    Hegi, Monika E.
    Gorlia, Thierry
    Erridge, Sara
    Grujicic, Danica
    Steinbach, Joachim Peter
    Wick, Wolfgang
    Tarnawski, Rafal
    Nam, Do-Hyun
    Weyerbrock, Astrid
    Hau, Peter
    Taphoorn, Martin J. B.
    Nabors, Louis B.
    Reardon, David A.
    Van den Bent, Martin J.
    Perry, James R.
    Hong, Yong Kil
    Hicking, Christine
    Picard, Martin
    Weller, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [10] Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX) followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study.
    Wick, W.
    Steinbach, J.
    Combs, S. E.
    Platten, M.
    Hartmann, C.
    Wenz, F. K.
    Boecker, U.
    Stoffregen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
1